Literature DB >> 26549675

Recurrent glioblastoma: Current patterns of care in an Australian population.

Sagun Parakh1, Vicky Thursfield2, Lawrence Cher1, Michael Dally3, Katharine Drummond4, Michael Murphy5, Mark A Rosenthal6, Hui K Gan7.   

Abstract

This retrospective population-based survey examined current patterns of care for patients with recurrent glioblastoma (rGBM) who had previously undergone surgery and post-operative therapy at original diagnosis. The patients were identified from the Victorian Cancer Registry (VCR) from 2006 to 2008. Patient demographics, tumour characteristics and oncological management were extracted using a standardised survey by the treating clinicians/VCR staff and results analysed by the VCR. Kaplan-Meier estimates of overall survival (OS) at diagnosis and progression were calculated. A total of 95 patients (48%) received treatment for first recurrence; craniotomy and post-operative treatment (38), craniotomy only (34) and non-surgical treatment (23). Patients receiving treatment at first progression had a higher median OS than those who did not (7 versus 3 months, p<0.0001). All patients progressed after treatment for first progression with 43 patients (45%) receiving treatment at second progression. To our knowledge this is the first population-based pattern of care survey of treatment for rGBM in an era where post-operative "Stupp" chemo-radiation is standard. First and second line therapy for rGBM is common and associated with significant benefit. Treatment generally includes re-resection and/or systemic therapy.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Recurrent glioblastoma; Survival

Mesh:

Year:  2015        PMID: 26549675     DOI: 10.1016/j.jocn.2015.08.025

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  3 in total

1.  Outcomes after second surgery for recurrent glioblastoma: a retrospective case-control study.

Authors:  Alysson Wann; Patrick A Tully; Elizabeth H Barnes; Zarnie Lwin; Rosalind Jeffree; Katharine J Drummond; Hui Gan; Mustafa Khasraw
Journal:  J Neurooncol       Date:  2018-01-02       Impact factor: 4.130

2.  Assessing the efficacy of repeat resections in recurrent glioblastoma: a systematic review.

Authors:  David Botros; Hayden Dux; Carrie Price; Adham M Khalafallah; Debraj Mukherjee
Journal:  Neurosurg Rev       Date:  2020-06-13       Impact factor: 3.042

3.  Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin.

Authors:  Hui K Gan; Sagun Parakh; Andrew B Lassman; Aidan Seow; Eddie Lau; Sze Ting Lee; Malaka Ameratunga; Yuliya Perchyonok; Diana Cao; Ingrid J G Burvenich; Graeme J O'Keefe; Angela Rigopoulos; Erica Gomez; David Maag; Andrew M Scott
Journal:  Neurooncol Adv       Date:  2021-08-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.